Table 1.
Clinical characteristics
| Ischemic heart disease, n=120 |
Controls, n=30 |
P-value | |
|---|---|---|---|
| Age, years, Med (range) | 62 (30–79) | 59 (28–73) | 0.15 |
| Male | 108 (90) | 17 (57) | <0.001 |
| BMI, kg/m2, Med (IQR) | 27·4 (24·8–30·5) | 26·2 (24·1–29·1) | 0.16 |
| LVEF, %, Med (range) | 34 (15–50) | 67 (54–79) | <0.001 |
| LVEF = 40–50% | 29 (24) | 0 | |
| LVEF = 31–39% | 39 (39) | 0 | |
| LVEF = 25–30% | 29 (24) | 0 | |
| LVEF = < 25% | 23 (13) | 0 | |
| Hypertension | 105 (88) | 23 (77) | 0.13 |
| Hyperlipidemia | 91 (76) | 10 (33) | <0.001 |
| Diabetes mellitus | 47 (39) | 2 (7) | <0.001 |
| COPD | 25 (21) | 4 (13) | 0.35 |
| Renal dysfunction | 32 (27) | 0 | 0.001 |
| Major depression | 25 (21) | 8 (27) | 0.49 |
| Stroke | 19 (16) | 1 (3) | 0.072 |
| Syncope | 29 (24) | 1 (3) | 0.011 |
| Non-sustained VT | 27 (23) | 1 (3) | 0.78 |
| Beta-blocker | 107 (89) | 18 (60) | <0.001 |
| Class III (Sotalol, Amiodarone) | 27 (22) | 2 (7) | 0.05 |
| Statins | 88 (73) | 7 (23) | <0.001 |
| Diuretics | 83 (69) | 7 (23) | <0.001 |
| Antidepressants | 16 (13) | 15 (17) | 0.64 |
| Follow-up, years, Med (mean±SD) | 6.8 (5.9±2.5) | 8.7 (8.5±1) | <0.001 |
| ICD implanted | 70 (58) | 0 | <0.001 |
| ICD therapy | 35 (50) | 0 | <0.001 |
| History of myocardial infarction | 120 (100) | 0 | <0.001 |
| 1-vessel disease* | 23 (19) | 0 | <0.001 |
| 2-vessel disease* | 22 (18) | 0 | <0.001 |
| 3-vessel disease* | 75 (63) | 0 | <0.001 |
Data are n (%), unless otherwise indicated; Med=median (Q1–Q3); test used: Wilcoxon test or chi-square test. Renal dysfunction=persistent serum creatinine >1.2mg/dl.
*
from coronary angiography